Cable Viewer

Currently released so far... 6693 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11

### Browse by creation date

66 72 73 75 79 85 86 88 89 90 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03
1986/05
1988/01
1989/12
1990/01 1990/07 1990/08 1990/10
1996/11
1997/12
2000/06 2000/09 2000/11
2001/02 2001/03 2001/07 2001/10 2001/11
2002/02 2002/03 2002/04 2002/07 2002/11 2002/12
2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown
Embassy Guatemala Embassy Gaborone Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Hermosillo Consulate Hamburg
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USNATO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy New Delhi Embassy Nassau Embassy Nairobi Consulate Naples
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate Shenyang Consulate Shanghai Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Tijuana
USUN New York USEU Brussels US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ASEC AO AF AE AFFAIRS AL AMGT APER AR AJ AG AM AORC ADCO AU ABLD ACOA AS AFIN AA AEMR AMED ATFN AROC AFGHANISTAN AFU AER ALOW AODE ABUD ATRN APECO ASUP AC AZ AVERY APCS ASIG AGMT AMBASSADOR ASEAN AX AID ASECKFRDCVISKIRFPHUMSMIGEG ADANA
BRUSSELS BR BY BO BC BM BEXP BL BTIO BA BE BK BU BIDEN BF BBSR BH BB BILAT BG BT BX BMGT BTIU
CU CH CO CI CE COUNTER CJAN CMGT CVIS CA CASC CDG CACM CDB CBW CPAS CAN CY CD CM COE COUNTRY CLEARANCE CACS CWC CG CF CS CN CT CL CIA CIS CTM CB CLINTON CR COM CONS CV CJUS CKGR COUNTERTERRORISM CODEL CONDOLEEZZA CARSON CW
DISENGAGEMENT DOD DJ DEAX DA DOE DK DHS DR DEA DS DOMESTIC DAO DCM DEPT DTRA DPRK
ECON ETRD EFIN EAID EUN ES EAIR EU ECIN EINV EG EINVEFIN ELAB ENRG ETTC EC EAGR ECPS EPET EIND EWWT EMIN ECIP EINDETRD EN EUC EI EREL EINT EFIS ER ENVR ECA ELN ET ENERG ENGY ELECTIONS EZ ELTN EK ECONCS EINVETC ECONEFIN ENIV ESA ENGR ETC EFTA ETRDECONWTOCS EXTERNAL ENVI EUNCH EINVECONSENVCSJA ECONOMICS EINN EFINECONCS ETRDEINVECINPGOVCS ECUN ENNP EUR EAP EEPET ETRDEINVTINTCS ETRO ESENV ECINECONCS
FR FBI FAO FARC FREEDOM FI FTAA FJ FINR FMLN FOR FOREIGN
GV GAZA GG GM GTMO GH GR GE GA GT GCC GZ GOV GOI GTIP GY GANGS
HO HURI HA HU HR HSTC HILLARY HK HYMPSK HUMAN
IR IZ IS ISRAELI IN IT IAEA ICTY IV INTERPOL IPR INRB IC IL IO IWC IIP IA ID ITALIAN ITALY ICAO IRAQI ILC IQ IMO INRA INRO IRAJ IF ICRC ILO IBRD IMF IZPREL ITPHUM ITPGOV INTELSAT IEFIN INR IRC IACI ITRA ICJ INTERNAL
JUS JO JAMES JA JOSEPH JP JOHNNIE JM
KAWK KISL KPAO KSPR KPRP KDEM KIPR KIRF KWBG KPAL KJUS KCRM KNNP KTFN KPKO KU KV KSCA KS KN KCOR KE KDRG KBCT KTIP KG KMDR KGHG KHLS KTIA KFRD KAWC KPWR KSUM KWAC KMIG KOLY KZ KSEC KIFR KDEMAF KFIN KNUC KPIN KHIV KBIO KPLS KIRC KMCA KWMN KVPR KACT KGIC KRAD KCIP KUNR KOMC KSTC KFLU KPRV KBTR KERG KTDB KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KSTH KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KSEP KMPI KNUP KTER KCFE KVIR KDDG KMRS KHDP KPAK KNAR KREL KBTS KNPP KCOM KGIT KNNPMNUC KO KPOA KRFD KHUM KDEV KICC KCFC KREC KWWMN KLIG KTBT KOCI KFLO KWMNCS KIDE KSAF KNEI KR KTEX KNSD KOMS KCRS KGCC KWMM KRVC KPAI KHSA KTLA KFSC KX KFTFN
LY LE LG LH LI LOG LO LT LTTE LU LAB
MOPS MASS MARR MCAP MIL MTCRE MO MNUC MPOS MX MAR MD MZ MEPP MA MR ML MOPPS MAPP MU MP MY MT MASC MK MI MAPS MCC MASSMNUC MQADHAFI MTCR MTRE MG MEPI MDC MEETINGS MUCN MRCRE MAS MTS MLS MERCOSUR MC MV MEDIA
NL NATO NI NG NO NIPP NU NPT NSG NA NS NZ NATIONAL NP NAR NE NASA NK NT NSF NPG NGO NSSP NRR
OVIP OTRA OPRC OSCI OTR OREP ODIP OPDC OAS OEXC OIIP OPCW OSCE OPIC OFFICIALS OFDP OECD OSAC OIE OVP OPAD OFDA OIC
PREL PGOV PTER PARM PHUM PK PINS PINR PA PBTS PEPR POL PALESTINIAN PHSA PL PAK PE PINT PU PREF PROP PO PECON PM POGOV PINL PKFK PMIL PY PFOR PHALANAGE PARTY PAO PRAM PMAR POLITICS PHUMPREL PHUS PRL PGOC PNR PGGV PNAT PROV PTERE PGOF PHUMBA PEL PLN POV PSOE PF PARMS PBIO PSI POLINT POLITICAL PARTIES PGOVLO PORG PGOVE PINF PRELP PAS PPA PRGOV PUNE PG POLICY
QA
RS RU RW RO RF ROBERT RFE REGION RP RIGHTS RICE RSP REACTION
SP SI SA SNAR SCUL SOCI SY SU STEINBERG SN SMIG SO SENV SR SF SG SW SL SIPRS SZ SH SOFA SANC SK ST SC SEVN SAN SHUM SYR SAARC SNARCS
TU TI TW TBIO TSPA TERRORISM TS TX TPHY TRGY TIP TC TH TZ TK TSPL TNGD TR TD TT TRSY TO TP TURKEY TFIN TINT
USEU UK UP UZ UNMIK UN US UNSC UG UY UNGA UNO UV UNHRC UNESCO UNEP UNDP UNCHS UNAUS USTR UNVIE UE USAID UNHCR USUN UNDC UAE UNDESCO UNCHC
VE VZ VN VT VM VTPREL
WTRO WTO WB WWARD WHA WI WHO WA WMO WEU WZ WITH WTRQ WBG
XY XD XW XF XA XG XT XM XR XS XL XH XZ XE XK XC XV
YM YI YE YMCS
ZP ZR ZI ZU ZB ZF ZA ZOELLICK ZK ZJ ZANU ZO

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 04WELLINGTON596, NEW ZEALAND-AUSTRALIA REGULATORY AGENCY TO RAISE INDUSTRY'S COSTS

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #04WELLINGTON596.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
04WELLINGTON596 | 2004-07-13 04:04 | 2011-03-21 00:12 | CONFIDENTIAL | Embassy Wellington
Appears in these articles: http://liberation.typepad.com/files/wellington-us-embassy-cables---bryce-edwards.pdf

`

    This record is a partial extract of the original cable. The full text of the original cable is not available.

` `

    C O N F I D E N T I A L SECTION 01 OF 02 WELLINGTON 000596

    SIPDIS

    STATE PASS USTR FOR BWEISEL
    STATE PASS FDA FOR OFFICE OF INTERNATIONAL PROGRAMS/WALTER
    BATTS AND JULIA HO
    STATE FOR EAP/ANP AND EB/TPP/BTA/ANA
    COMMERCE FOR 4530/ITA/MAC/AP/OSAO/GPAINE

    E.O. 12958: DECL: 07/12/2014
    TAGS: ETRD NZ
    SUBJECT: NEW ZEALAND-AUSTRALIA REGULATORY AGENCY TO RAISE INDUSTRY'S COSTS

    REF: A. AUCKLAND   118
    ¶B. 03 WELLINGTON   1273
    ¶C. 03 WELLINGTON   1191
    ¶D. 01 WELLINGTON   798

    (U) Classified by DCM David R. Burnett. Reasons: 1.5 (b) and (d).

    ¶1. (C) Summary: U.S. makers of medical devices and dietary
    and nutritional supplements face the prospect of additional
    regulatory costs to enter the New Zealand market -- but
    perhaps not as high as the industry had feared. An
    Australian-New Zealand authority to regulate therapeutic
    products in both countries probably will accept U.S.
    certification of products, and not just European
    certification, as the industry had expected. On the other
    hand, the agency will aim to recover all regulatory costs
    from the industry. Representatives of U.S. manufacturers
    fear such costs could drive many of their products out of the
    New Zealand market.

    ¶2. (U) Meanwhile, the pharmaceutical industry has endorsed
    the joint authority, while worrying that the agency will ban
    direct-to-consumer advertising. Such advertising has helped
    a number of pharmaceutical companies to boost sales of
    unsubsidized medicines in New Zealand. It has provided one
    of the few means available in a highly restricted market for
    pharmaceutical manufacturers to build sales for products that
    consumers pay for entirely out of pocket. End summary.

    New regulation
    --------------

    ¶3. (U) The Australian and New Zealand health ministers signed
    a treaty December 10 to set up a trans-Tasman agency to
    regulate therapeutic products, including medical devices,
    prescription and over-the-counter medicines, dietary and
    nutritional supplements, and cosmetics and toiletries (ref
    B). When the agency opens its doors in July 2005, it will
    replace the Australian Therapeutic Goods Administration (TGA)
    and the New Zealand Medicines and Medical Devices Safety
    Authority (Medsafe). Both governments are jointly working to
    establish a framework for the agency and instructions for any
    necessary legislation.

    ¶4. (U) For New Zealand, the agency offered a solution to a
    long-acknowledged deficiency. Medical devices and
    health-care products have been virtually unregulated in the
    country. Medsafe does evaluate pharmaceuticals before
    allowing them on the market. An adviser to the health
    ministers suggested the cost to New Zealand of participating
    in the joint agency would be less than if it had tried on its
    own to extend its regulatory authority to devices and other
    non-drug medical products.

    Higher costs
    ------------

    ¶5. (C) Nonetheless, the adviser, Selwyn Katene, acknowledged
    that New Zealand's regulatory costs would increase
    significantly under the joint agency. For example, the
    number of New Zealand-based staff members needed by the new
    agency would be at least double the 35 people who now staff
    Medsafe. Moreover, Katene noted that all the agency's costs
    would be passed on to the industry. Fees for registering
    products would be set to recover the costs of regulation,
    although Katene said his government recognizes it may need to
    phase in such fees to alleviate the pain to industry. But
    with regulation over non-drug products, Katene said, "the
    industry's halcyon days are over." Many distributors of
    medical devices and complementary goods expect the higher
    fees to harm their sales in New Zealand (ref C). They
    advocate setting fees according to the size of the product's
    market, with Australia's population being five times that of
    New Zealand.

    ¶6. (C) The joint authority initially had intended to require
    additional documentation and possibly a quality-control audit
    for products that do not have European certification yet have
    U.S. Food and Drug Administration (FDA) approval. However,
    Katene -- who asked that his comments July 9 not be shared
    with industry -- said New Zealand Minister of Health King had
    decided that requiring two certification processes was
    unreasonable.

    ¶7. (C) That decision should greatly relieve representatives
    of U.S. medical-device manufacturers, who have argued that
    additional certification would increase the cost and time for
    marketing their products. A number of representatives met
    with King on June 25 and -- according to Katene -- influenced
    her thinking on the issue. Katene, a New Zealander, serves
    as secretary to the joint agency's ministerial council, which
    is composed of the two health ministers. They will appoint
    the agency's five governing board members.

    Advertising's future
    --------------------

    ¶8. (C) On June 17, the Researched Medicines Industry
    Association of New Zealand (RMI) -- the pharmaceutical
    industry association -- announced in a news release its
    support of the joint agency. Lesley Clarke, RMI's chief
    executive, said July 9 that the association had long backed
    the concept of a joint authority, since it would provide one
    point of entry for pharmaceutical companies to both Australia
    and New Zealand. RMI issued the news release to bolster
    parliamentary support for the agency, after the media
    reported that the agency's compliance requirements could put
    medical-device and complementary-goods companies out of
    business.

    ¶9. (C) However, the pharmaceutical industry worries that the
    new agency could mean an end to its ability to advertise its
    unsubsidized prescription medicines directly to New Zealand
    consumers (ref A). Australia allows only disease-based,
    awareness-building advertising, with no mention of product
    names. Some pharmaceutical companies have built a
    significant private purchase market in New Zealand -- in one
    case, as much as one-third of its sales -- as a way to
    counter the limits of a system of government-subsidized sales.

    ¶10. (C) On that issue, Katene would say only that Minister
    King had been instructed by the cabinet to "harmonize" with
    Australia and that a decision for or against
    direct-to-consumer advertising had not been made.
    "Harmonization" generally has been thought to refer to New
    Zealand's adopting the Australian rules, with Australia
    seeing no need to change.

    ¶11. (C) Clarke said that, other than Minister King, members
    of Parliament are supportive of or ambivalent about
    direct-to-consumer advertising. Only Minister King appears
    to be adamantly against it, joining a small doctors' group --
    and no consumer groups -- that advocates a ban. Clarke
    predicted that such advertising would continue to be allowed,
    with a ban requiring the repeal of existing law and with
    Minister King lacking her colleagues' support.

    ¶12. (C) Comment: Allowing FDA certification would remove one
    potentially discriminatory barrier to U.S. products. Post
    remains concerned, however, about the potential decline in
    sales of U.S. medical devices and other therapeutic products
    due to anticipated higher regulatory costs and about the
    possibility that pharmaceutical companies -- already
    constrained by New Zealand government policy -- would lose
    their ability to generate private sales through advertising.
    Post hopes these concerns could be conveyed in the Trade and
    Investment Framework Agreement talks with New Zealand
    scheduled for July 20.

    Swindells

`